These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25122424)

  • 1. A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.
    Drilon A; Sugita H; Sima CS; Zauderer M; Rudin CM; Kris MG; Rusch VW; Azzoli CG
    J Thorac Oncol; 2014 Sep; 9(9):1272-7. PubMed ID: 25122424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer.
    Toyooka S; Maruyama R; Toyooka KO; McLerran D; Feng Z; Fukuyama Y; Virmani AK; Zochbauer-Muller S; Tsukuda K; Sugio K; Shimizu N; Shimizu K; Lee H; Chen CY; Fong KM; Gilcrease M; Roth JA; Minna JD; Gazdar AF
    Int J Cancer; 2003 Jan; 103(2):153-60. PubMed ID: 12455028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
    Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
    Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
    Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiles of lung tumors.
    Toyooka S; Toyooka KO; Maruyama R; Virmani AK; Girard L; Miyajima K; Harada K; Ariyoshi Y; Takahashi T; Sugio K; Brambilla E; Gilcrease M; Minna JD; Gazdar AF
    Mol Cancer Ther; 2001 Nov; 1(1):61-7. PubMed ID: 12467239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
    Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
    Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Takahashi N; Shimazaki Y; Motoyama T
    Cancer Sci; 2003 Jul; 94(7):589-92. PubMed ID: 12841866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
    Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
    Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation markers and early recurrence in stage I lung cancer.
    Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
    N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
    Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
    Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
    Wang Y; Zhang D; Zheng W; Luo J; Bai Y; Lu Z
    Cancer; 2008 Mar; 112(6):1325-36. PubMed ID: 18286531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China.
    Huang X; Wu C; Fu Y; Guo L; Kong X; Cai H
    Bull Cancer; 2018 Sep; 105(9):746-754. PubMed ID: 30126609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.
    Feng Q; Hawes SE; Stern JE; Wiens L; Lu H; Dong ZM; Jordan CD; Kiviat NB; Vesselle H
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):645-54. PubMed ID: 18349282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
    Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
    Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.
    Lin Q; Geng J; Ma K; Yu J; Sun J; Shen Z; Bao G; Chen Y; Zhang H; He Y; Luo X; Feng X; Zhu J
    J Cancer Res Clin Oncol; 2009 Dec; 135(12):1675-84. PubMed ID: 19506903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.